^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    IPH5301

    i
    Other names: IPH5301, IPH53, IPH 5301, IPH 53, anti-huCD73 mAb
    Associations

    News

    Trials
    Company:
    Innate
    Drug class:
    CD73 inhibitor
    Related drugs:
    Associations

    News

    Trials
    2ms
    CHANCES: A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=27, Recruiting, Institut Paoli-Calmettes | Trial completion date: Feb 2025 --> Feb 2026 | Trial primary completion date: Mar 2024 --> Mar 2025
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    HER-2 positive • HER-2 overexpression
    |
    Herceptin (trastuzumab) • paclitaxel • IPH5301